Emma Walmsley discusses GSK’s new collaboration with Sanofi to develop a adjuvanted COVID-19 vaccine.

Two of the largest vaccines companies in the world, GlaxoSmithKline (GSK) and Sanofi, are teaming up to hasten vaccine development for COVID-19.

“By combining our science and our technologies, we believe we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19”, said Emma Walmsley, chief executive officer of GSK, in a joint Sanofi-GSK press release on Tuesday.

“One of the important things in this collaboration is our combined scale. Both companies have significant manufacturing capacity,” Walmsley added in a separate video message.

“We still have a lot of work to do since this is still at an early stage of development. We believe that if successful, we’ll be able to make hundreds of millions of doses annually by the end of next year,” she said.

The collaboration was applauded by industry representatives as well. 

“Today’s announcement is an illustration of the biopharmaceutical industry’s strong sense of responsibility to act together and live up to its COVID-19 commitments, which include working in a concerted manner to increase industry’s manufacturing capabilities and willingly share available capacity to ramp up production once a successful vaccine or treatment is developed”, said Thomas Cueni , Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) told Health Policy Watch.

The recent alliance aims to combine Sanofi’s protein-based vaccine with GSK’s adjuvant technology. Adjuvants are commonly added to protein-based vaccines to boost the immune response to the vaccine, allowing the vaccine to be more effective at lower doses. This makes the vaccine easier to mass produce. 

The companies have entered into a Material Transfer Agreement to enable them to start working together immediately. Definitive terms of the collaboration are expected to be finalised over the next few weeks.

If the new vaccine candidate is successful in Phase 1 Clinical Trials planned for late 2020, it will be available in the first 6 months of 2021, says the joint Sanofi-GSK press release.

The companies have established a Joint Collaboration Task Force for the project, co-chaired by David Loew, Global Head of Vaccines, Sanofi and Roger Connor, President Vaccines, GSK. The Biomedical Advanced Research and Development Authority (BARDA), an arm of the US Department of Health and Human Services (HHS), has already committed to funding part of the Sanofi vaccine’s development.

Image Credits: Heather Hazzan, GSK.

[Unitaid]

Geneva, Switzerland (14 April 2020) – Unitaid marked the first World Chagas Disease Day with the release of a comprehensive report on how to better confront the potentially deadly parasitic infection that strikes hardest among Latin America’s poor and marginalized.

It was on this date in 1909 that a Brazilian doctor, Carlos Chagas, diagnosed the first case of what was to be called Chagas disease.

Unitaid is also developing an initiative to help eliminate mother-to-child transmission of Chagas disease as part of its mandate to improve maternal, newborn and child health.

“Unitaid was created to speed equitable access to innovative health solutions, and we are thrilled to join global efforts against this insidious disease,” Unitaid Executive Director a.i. Philippe Duneton said. “Access to simpler and more affordable test and treat tools will help end the suffering Chagas causes, and cut costs for families and health systems.”

Unitaid’s work aligns with global health plans that call for eliminating Chagas disease as a public health problem by 2030.  Currently, only an estimated 7 percent of people with Chagas disease get diagnosed, and only 1 percent receive effective treatment.

Unitaid’s just-released report, Technology and Market Landscape for Chagas Disease, maps out the diagnostics and treatments that are in use now and identifies innovations that could improve upon them. The report also examines market barriers that could be removed to make way for better tests and treatments.

Unitaid’s upcoming investment to tackle mother-to-child transmission seeks to address some of these challenges, notably the lack of diagnostic tools and medicines in primary health care clinics. At least two million women of child-bearing potential are chronically infected with ‘Trypanosoma cruzi’, but active screening and optimal treatment can prevent transmission to their babies. In addition, early detection of infection in infants can greatly reduce the number of hospitalizations and deaths related to Chagas disease.

Transmitted by the blood-sucking triatomine bug, Chagas disease (American trypanosomiasis), slowly brings on cardiac, neurological and digestive problems. Up to 7 million people are thought to be infected with it, 75 million people are considered to be at risk of infection and about 10,000 die from it annually. In Brazil, Chagas disease causes more deaths than any other parasitic disease, including malaria.

In the last decades, the disease has moved from the countryside to urban settings, and is now found outside the borders of the 21 Latin American countries where it is endemic. Cases now appear in places such as the United States, Europe, Canada, Japan and Australia.


For more information: Gloria Vinyoles | 41 79 121 18 65 | vinyolesg@unitaid.who.int

Image Credits: Unitaid.

Dr Tedros at WHO’s regular press briefing on COVID-19

WHO Director General Dr. Tedros Adhanom Ghebreyesus said on Monday that the relationship between WHO and the United States is “very good” and that, despite the recent maelstrom of criticism by President Donald Trump over WHO’s handling of the COVID-19 crisis, he hoped that funding from the USA will continue. 

“I hope the funding to WHO will continue. And the relationship we have is very good. And we hope that this will continue,” said Dr Tedros at a press briefing.

The WHO Director-General was responding after a rash of remarks late last week by Trump, other key White House figures and allies over the agency’s handling of the crisis, which Trump and some of his political allies have described as “China-centric.”  There have been suggestions, including from Trump, that the US might consider suspending its contributions to the organization, and Congressional Republicans have demanded more documentation about key exchanges between WHO and China over issues that arose in the early days of the outbreak, such as whether the virus could be transmitted, person-to-person. 

The USA is the biggest contributor of funding to the WHO and has provided US$ 400 million to the Organization in 2019, which was ten times more than China. 

Meanwhile, however, WHO received a big boost from another major donor country, the United Kingdom. The announcement of a contribution of £ 200 million came just after Prime Minister Boris Johnson was discharged from a hospital where he was treated in an intensive care unit for several days, crediting the British National Health Service (NHS) for “saving my life”. Dr. Tedros welcomed this “generous support” and urged other member countries to follow the UK’s initiative.

Countries Need To Be Wary of Lockdown “Exit Strategies” Even In Places Where Outbreak Has Stabilized 

Countries planning to lift their lockdowns must do so carefully and gradually, urged Mike Ryan, Executive Director of the WHO’s Health Emergencies Programme, at the press briefing. He underlined this as a key principle even as outbreaks have stabilized in a “pretty consistent way” for a number of European countries.

“Lockdowns can be lifted in certain strategic areas, maybe where there’s lower incidence. But it does have to happen slowly, it does have to happen in a very controlled manner. And it is important that the community understands this,” said Ryan. 

As countries begin to open up again, they must maintain aggressive surveillance, testing and community engagement to keep the outbreak at bay. “We need to have a much more stable exit strategy that allows us to move carefully and persistently away from lockdown. And the only way to do that is to have fully empowered communities and a fully activated public health architecture and to the strengthen health system”, said Mike Ryan.

It is also “really important” that the lifting of these measures doesn’t happen “all at once all over Europe”, added Maria Van Kerkhove, Technical Lead for the WHO’s Health Emergencies Programme, as this may trigger another outbreak wave.

Huge Unknowns About Coronavirus Contagion Period & Immunity Gained After Illness  

3D print of a spike protein of the SARS-CoV-2 virus

Scientists still don’t have a full picture of the immune response to COVID-19, and that is one of the other issues confounding policymakers as they try to make decisions about exit strategies.

People infected with COVID-19 produce antibodies, but it is unclear whether these antibodies confer immunity, and for how long, Ryan pointed out adding, “The data is quite limited.”

“Some individuals had a strong antibody response. Whether that antibody response actually means immunity is a separate question”, said  Kerkhove referring to a new study from Fudan University in Shanghai that has not been peer-reviewed yet. The study, which compared antibody responses of almost 200 patients, showed that some people infected with COVID-19 may not develop any antibodies at all.

Yet another big knowledge gap centers around the time during which people carrying the virus may transmit it to others, Kerkhove said.

Although most people infected with COVID-19 develop symptoms within five days, scientists do not know whether patients are contagious for several days or weeks. Polymerase Chain Reaction (PCR) tests, the lab-based gold standard for diagnostics, suggest that contagion could last several weeks. However, just because people with the mild disease test positive for several weeks does not necessarily mean that they are still contagious, said Kerkhove.

“We don’t have the full picture,” she said, “What we need is much more data from countries to actually be able to say, how long is someone contagious.” 

In light of limited testing capacity and unknowns about the length of time a person can be contagious, individuals in home isolation should stay at home until their symptoms resolve, and even continue isolating themselves for another two weeks after that as well, recommended Kerkhove.

“What we recommend right now is that those individuals are in home isolation, if they can’t be isolated in a medical facility, until their symptoms resolved, plus an additional 14 days”.

More data is also urgently needed to understand if the immune response is different between patients with mild and severe COVID-19, especially in those with severe infection that have recovered, added Kerkhove. Such studies will help researchers determine what type of immune response helps a patient clear SARS-CoV-2 safely and effectively from their body.

Many of the deaths associated with COVID-19 may also be due to an overreraction of the immune system, rather than the the virus itself, suggests a study published late last month. As part of the immune reaction, so-called “cytokine storms” can lead to an excess amount of immune cells piling up in the airways and blocking them off, leading to death.

WHO Softens Position on Masks 

Wearing masks to protect from COVID-19 in Nigeria (Photot: @CRSPHCDA1)

As mask use in the general population has gained momentum in various countries, including not only Asia, but the USA, eastern Europe and Israel, the WHO officials at the briefing expressed a more positive line on the practice, saying that they could support public use of masks as part of a comprehensive strategy. Previously, WHO’s Emergencies team had said mask use in the general population was unnecessary, except among people who are symptomatically ill, or caring for other sick household members.  

“The WHO will support countries who wish to implement a more broad based strategy of mask use “as long as it’s part of a comprehensive strategy”, said Ryan.

“[The comprehensive strategy] includes physical distancing. It includes hand hygiene. It includes respiratory etiquette. It includes staying home if you’re unwell. It includes cases being isolated confirmed cases being isolated. It includes contacts being in quarantine, and it includes following the directives of the national government”, added Kerkhove.

WHO has also stressed that masks, when worn or used improperly, can still lead to transmission of the virus.  This is supported by a recent study that found large quantities of SARS-CoV-2 can accumulate on masks. The study, which was published last Friday, recommends adequate desinfection of masks before discarding them.

“There are issues around wearing those face coverings and disinfecting those face coverings and disposing of those face coverings or masks”, said Ryan. 

But for those who know that they are ill, masks are not an alternative to self-isolation, emphasized Ryan. “We don’t want people to think that putting a mask on is the same as staying home and reporting the fact that you’re sick to authorities”, he said.

The WHO’s policy on broad-based mask use has been tweaked amid growing recognition that social isolation is unrealistic in some settings and communities, especially those in developing countries with high population densities, said Kerkhove at the press briefing. In addition, in places where transmission of the virus is high, many people who are in fact ill and contagious may be unaware of their status, experts have said. 

Total cases of COVID-19 as of 10:20PM CET 8 April 2020, with active case distribution globally. Numbers change rapidly.

Image Credits: NIAID, Cross River State Primary Health Care, Nigeria .

Photo: D Sharon Pruitt

Although there have been suggestions that warmer weather might lead to the waning of the COVID-19 pandemic in the Northern Hemisphere, a new study published by the United States National Academy of Sciences has dashed some cold water on that hypothesis, saying that available data on diease spread has so far failed to show strong seasonality.

The preliminary analysis by the National Academies’ Standing Committee on Emerging Infectious Diseases and 21st Century Health Threats said that the number of well-controlled studies showing reduced survival of the coronavirus in elevated temperatures and humidity is small, and urged caution not to over-interpret results. While some data, particularly from laboratory studies, provide evidence supporting seasonality, the researchers note that these are not necessarily representative of the natural environment and that multiple countries currently in their summer season are experiencing significant volume of transmission,

Even if warmer temperatures are less favorable for COVID-19, “given the lack of host immunity globally, this reduction in transmission efficiency may not lead to a significant reduction in disease spread without the concomitant adoption of major public health interventions,” the experts wrote.  Some countries in warm climate are also experiencing rapid virus spread, the experts added, so that “a decrease in cases with increases in humidity and temperature elsewhere should not be assumed.”

The report also notes that neither of the other coronaviruses that have recently leaped from animals to humans, Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), nor the flu strains of previous pandemics, have shown a seasonal pattern.

The study evaluated available observational epidemiological data as well as laboratory experimental data, including studies both in China and other countries. Further study is required to better characterize the virus’ transmission patterns, reported the Univeristy of Minnesota Center for Infectious Disease Research and Policy. 

COVID-19 Cases in Spain Rise Once More

After a week of decreasing daily COVID-19 incidence, Spain once more reported elevated numbers on 3 consecutive days. Today, Spain reported 5,756 new cases, bringing the national total to 152,446 cases, including 15,238 deaths (683 new), reported the Johns Hopkins Center for Health Security. Italy reported more new cases than the previous day (3,836 compared to 3,039), but the daily incidence remains below 4,000 for the third consecutive day after exceeding that number for nearly 3 weeks. Italy is reporting a total of 139,442 confirmed cases, and 17,669 deaths.

Meanwhile, while US President Donald Trump expressed hopes that the US could “reopen again soon” experts were more reserved in light of the continued increase in US cases, with some 30,000 more infections reported in the US over the past 24 hours, 10,000 more than on the day before.

In South-East Asia, cases also continued to rise in India, in partvcular, which has reported more than 500 new cases a day, over the past 10 days, for a 300% increase, There are now 6,412 cases in the country, according to the official India Ministry of Health and Family Welfare data.

Meanwhile, WHO Director General Dr. Tedros Adhanom Ghebreyesus brushed off recent criticism of WHO’s response to the COVID-19 crisis, which US President Donald Trump on Tuesday tweeted was “very China centric.”  At a later White House briefing Trump repeated his charge that WHO had been too soft on China’s early management of the emergency, and suggested that US funding to the organization would be re-examined. Trump also criticized WHO’s strong opposition throughout January and February to the imposition of travel restrictions to stop the spread of the virus, saying that the Organization should have recommended restrictions much earlier, which the US later adopted on unilaterally followed by countries around the world.

At a WHO press briefing on Wednesday, the WHO Director General urged political leaders not to play politics with the coronavirus emergency, adding: “why do I care about being attacked when people are dying.”

    Cumulative and active cases. Numbers change rapidly.

-Updated 4 April, 2020

Image Credits: D Sharon Pruitt.

An N95 respirator, used during the COVID-19 pandemic to protect healthcare workers against infection

Dutch Deputy Prime Minister Hugo de Jonge on Wednesday offered to support the World Health Organization to develop a pool of intellectual property rights for COVID-19 technologies, just days after WHO Director-General Dr Tedros Adhanom Ghebreyesus announced WHO’s public support for the initiative.

“In principle, I am sympathetic to this initiative,” Minister de Jonge wrote in an update on the Netherlands’ COVID-19 response on Tuesday. “The development of this initiative in relation to the availability and affordability of vaccines must take place in the coming period.”

This makes the Netherlands the latest country to back a call by Costa Rica to establish a freely accessible pool of rights for tools to fight the pandemic. Rights holders would voluntarily contribute IP rights on any data, treatments, diagnostics, vaccines, or COVID-19 technologies to the pool, which would then be made available to a number of manufacturers to quickly scale up production and access to such tools.

These rights “must be made available to everyone for free, or for a reasonable license fee,” said de Jonge.

Dr Tedros first publicly announced WHO’s commitment to the Costa Rica proposal on Monday, adding that WHO was currently working with Costa Rica to “finalize the details.”

The Board of UN-backed Medicines Patent Pool, which manages a “pool” of patent rights for essential medicines, announced its support for the COVID-19 IP pool last week, temporarily expanding its mandate outside of medicines and treatments.

Kentucky Governor Requests 3M Release N95 Patent

Kentucky Governor Andy Beshear called on the United States-based company 3M to release its patents for N95 respirators – a type of protective mask in desperately short supply during the COVID-19 pandemic.

“The procurement is incredibly difficult, as is the manufacture because it’s under patent,” Beshear said in a press conference on 1 April. He added that it was the company’s “patriotic duty” to license the N95 patents “to the nation” during the pandemic so that “everybody else can manufacture it.”

While 3M is not the only producer of N95s, it is the largest domestic producer. The company holds 441 patents in the US that mention ‘N95’ or ‘respirator,’ according to a list from James Love, director of Knowledge Ecology International, a patent watchdog group. The newest respirator-related patent granted to 3M was approved just yesterday, on 7 April 2020.

The respirators are used by healthcare workers in order to protect against the virus, and offer much better protection than surgical masks. However, due to the extreme shortage of respirators around the world, most hospitals in the US are running low or completely out of the protective masks. Many have resorted to rationing the N95s to one per physician every two to three days, or collecting and sanitizing them after use. Under normal circumstances, N95s are discarded after each use.

Beshear’s comments come just on the wake of US President Donald Trump’s invocation of the ‘Defense Production Act,’ a Korean War era law that allows the federal government to redirect domestic industries’ capacities towards wartime production.

See The Courier Journal for more on this story.

Image Credits: OSHA's Respiratory Protection Standard 29 CFR 1910.134.

Community health worker distributes Mectizan (ivermectin) to eliminate river blindness

While much of the public fanfare around new COVID-19 drugs has centered around the lupus drug, hydroxychloroquine, and a failed Ebola remedy, remdesivir, other researchers are keen to explore the potential of other time-worn remedies – although here, too, experts are urging extreme caution.   

Ivermectin, the antiparasitic drug that turned the tide in the West African fight against river blindness (onchocerciasis) some 30 years ago has been found to slow the growth in the laboratory of SARS-CoV-2, the virus behind COVID-19. Meanwhile, a widely circulated preprint study claiming that countries with mandatory Bacillus Calmette-Guérin (BCG) vaccination against tuberculosis may experience lower rates of COVID-19 cases and deaths has led to the initiation of at least two clinical trials on the prophylactic use of BCG in Australia and the Netherlands, with more countries planning on follow suit.

Still, the concentrations of ivermectin that were demonstrated as effective against SARS-CoV-2 in the laboratory cell culture experiments are “far beyond” dosage levels approved by the FDA to safely treat river blindness in humans, warned the Mectizan Donation Program, in an Expert Committee Statement, issued on Tuesday. High doses of ivermectin have shown “serious toxicity” in animal studies, they added.

In the laboratory trial, the single dose of ivermectin [Mectizan®] slashed the growth of SARS-CoV-2 by 5000-times within 48 hours, reported the study published in Antiviral Research last Friday. 

Clinical trials would be needed to determine if there is a dose of ivermectin that is both safe for humans and effective against the SARS-CoV-2, and even expedited human safety trials can take time, a WHO scientist told Health Policy Watch

“There is a long path from showing something works at certain concentrations in [cell culture studies] on the virus to showing that the required concentrations can be achieved in the target tissues in humans and are expected to be safe for humans,”  said the scientist.

Then, the drug would also have to be studied further in randomized controlled studies in COVID-19 patients, and must be proven to demonstrate “clinical benefit,” added the scientist. 

Millions of doses of the FDA-approved medication are donated every year to oncho-endemic countries through the Mectizan Donation Programme created by Merck Sharpe & Dohme (MSD), which developed the drug in collaboration with the TDR, the WHO-hosted Special Programme for Research and Training in Tropical Diseases, in the late 1970s. Ivermectin is typically administered once a year in communities of West Africa where onchocerciasis is endemic, to prevent the development of the disease, which can lead to blindness when it goes untreated. 

BCG Clinical Trials Beginning in Australia and Netherlands  – But Researchers Warn Against Complacency in Countries Where Vaccine is Widely Used 

Similarly, researchers have questioned the validity of the BCG vaccine study, urging for more robust studies on the effectiveness of the vaccine.

The initial pre-print study by researchers at the New York Institute of Technology found that in 28 middle- and high-income countries, which did not require BCG vaccination, there were also higher numbers of COVID-19 cases per capita and higher death rates than in countries that enforced universal BCG vaccination. BCG is a vaccine typically given to infants, which protects against tuberculosis in young children, although protection wanes by age 12. The vaccine has been demonstrated to induce a more general immune response, which may offer protection against other respiratory diseases. The study was published on the preprint server MedRxiv in mid-March, which means that it has not yet been peer-reviewed.

“Accepting these findings at face value has the potential for complacency in response to the pandemic, particularly in low- and middle-income countries [where BCG vaccination is highly prevalent]” warned infectious disease researchers Emily Maclean, Lena Faust, Sophie Huddart, and Anita Svadzian of McGill’s International TB Centre in Canada, in a searing critique published in Nature Microbiology Community

“The pre-print’s study design, timing of analysis and data collection, lack of adjustment for important confounders, and uncertain biological plausibility mean that we cannot view the paper’s findings as causal,”  Maclean told Health Policy Watch. 

Rather, she said, this type of ecological study, which only observes broad population level data, should be “hypothesis generating”. Under normal circumstances, such a study would spark more epidemiological studies and early phase clinical trials to test the vaccines’ safety and efficacy.

“However, given that we’re in extraordinary times, I think following up on promising vaccine leads is a good choice,” said Maclean, particularly because scientists already know the long-established vaccine is “safe for use” to humans.

“Ethically- and properly-conducted randomized control trials will allow us to see if BCG has a causal effect regarding COVID-19 morbidity and mortality,” she added. 

That’s exactly the step that some countries are taking. Phase III clinical trials to test the BCG vaccine in healthcare workers have begun in the Netherlands and in Australia, and researchers in the United States are also exploring ways to begin trials. The Inserm Research Director at the Institut Pasteur in Lille France, Camille Locht, is preparing for the implementation of a double-blind clinical trial in collaboration with Spain. 

Still, the vaccine is not a “panacea” warned Nigel Curtis, coordinator of the clinical trial in Australia, to the the New York Times. Both the Australian and the Dutch trials will aim to only assess whether the vaccine would reduce the duration of illness, thus allowing sick healthcare workers to recover more rapidly and return to work.

Japanese BCG vaccination kit

WHO Africa Region Hits 10,000 Cases

The WHO Africa region, which encompasses most of Sub-Saharan and Southern Africa, hit a sober new mark on Tuesday when the region surpassed 10,000 cases.

“COVID-19 has the potential not only to cause thousands of deaths, but to also unleash economic and social devastation. Its spread beyond major cities means the opening of a new front in our fight against this virus,” said WHO Regional Director for Africa Matshidiso Moeti in a press release.

Moeti urged for a “decentralized response” tailored to the local context across the continent. “Communities need to be empowered, and provincial and district levels of government need to ensure they have the resources and expertise to respond to outbreaks locally,” she added.

Of particular concern are countries with fragile health systems experiencing complex emergencies – some countries in Africa do not have the hospital bed capacity, enough ventilators, and trained personnel to take care of a surge of patients.

“Africa still has an opportunity to reduce and slow down disease transmission.  All countries must rapidly accelerate and scale up a comprehensive response to the pandemic, including an appropriate combination of proven public health and physical distancing measures,” said Ahmed Al-Mandhari, WHO’s Regional Director for the Eastern Mediterranean, which includes North African countries such as Egypt, Morocco, and Tunisia.

South Africa, with 1,749 cases and 13 deaths, has the highest number of cases, but the death rate so far is highest in Algeria with 205 deaths and 1,572 cases.

Total cases of COVID-19 as of 7:30PM CET 8 April 2020, with active case distribution globally. Numbers change rapidly.

Image Credits: Mectizan Donation Programme, Y Tambe, Johns Hopkins CSSE.

Nurses are on the frontline of the COVID-19 response in Thailand, where public sector nurses have been fighting for pay raises.

The world needs 6 million more nurses in the next 15 years in order to reach the Sustainable Development Goals, according to the first-ever State of the World’s Nursing report released by the World Health Organization, Nursing Now, and the International Council of Nurses.

The report, released Tuesday on World Health Day, explores challenges and successes faced by the world’s largest cadre of health workers, whose essential roles have been highlighted even more dramatically during the COVID-19 pandemic. 

Nurses are the backbone of any health system. Today, many nurses find themselves on the frontline in the battle against COVID-19,” said WHO Director General Dr Tedros Adhanom Ghebreyesus, in a press release. ‘This report is a stark reminder of the unique role they play, and a wakeup call to ensure they get the support they need to keep the world healthy.’

“[The report] shows very clearly that we do not have enough nurses to meet the challenge of the SDG of Health for All by 2030 and that we will need to raise the number of qualified nurses by at least 6 million by 2030 to achieve that aim,” said Mary Watkins, co-chair of Nursing Now.

There are just under 28 million certified nurses working around the world today. However, the distribution of nurses is highly unequal – approximately 80% of nurses serve only 50% of the world’s population. The greatest shortages of nurses are in Africa, South East Asia and the WHO Eastern Mediterranean region as well as some parts of Latin America. 

But governments all over must increase investment in nursing education, protections and pay for nurses – even high-income countries. “Individually, professionally, morally of course we all value nurses – but not economically,” said Howard Catton, chief executive officer of the International Council of Nurses. Shortages of nurses in poorer countries are exacerbated by “an over-reliance in high-income countries on migration” to supply nursing staff.

“Wealthier countries are not producing enough nurses and are hiring them from ‘less fortunate’ countries at higher wages than can be achieved in their home countries,” added Watkins. 

The largest shortages of nurses are seen in some parts of Latin America, Africa, and Southeast Asia.

Globally, nurses make up nearly 60% of the health workforce, but only 25% of the education budget is spent on them. Nurses’ pay is highly affected by austerity measures – just as one example, nurses in Zimbabwe are only paid US $60 per month despite rampant inflation raising the cost of living.

In light of the global shortage of personal protective equipment during the COVID-19 emergency, governments must also work on improving nurses’ working conditions, according to the report.

“There is a real need to see that employment terms are attractive for nurses, not only in terms of remuneration but also safety, both in terms of violence and sufficient personal protection equipment,” said Watkins. 

Additionally, nursing is a “female-dominated profession” with “a history of discrimination and inequality, pay and gender biases,” added Catton. The report noted that over 90% of the world’s nurses are women, but most leadership roles in nursing are held by men. 

“Our nurses are the bedrock of preparedness and strong health systems,” he added. “We need a change in thinking and mindsets about the value of nursing.”

The State of the World’s Nursing report recommended ten key steps to increase investment in nursing:

  • increase funding to educate and employ more nurses;
  • modernize professional nursing regulation by harmonizing education and practice standards and using systems that can recognize and process nurses’ credentials globally;
  • strengthen capacity to collect, analyze and act on data about the health workforce;
  • monitor nurse mobility and migration and manage it responsibly and ethically;
  • educate and train nurses in the scientific, technological and sociological skills they need to drive progress in primary health care; 
  • establish leadership positions including a government chief nurse and support leadership development among young nurses;
  • ensure that nurses in primary health care teams work to their full potential, for example in preventing and managing noncommunicable diseases;
  • improve working conditions including through safe staffing levels, fair salaries, and respecting rights to occupational health and safety; 
  • implement gender-sensitive nursing workforce policies; and
  • strengthen the role of nurses in care teams by bringing different sectors (health, education, immigration, finance and labour) together with nursing stakeholders for policy dialogue and workforce planning. 

In light of the COVID-19 pandemic, which has revealed weaknesses in health systems around the world, implementation of the report’s recommendations is  “not optional or ‘nice-to-do’”, it is a “must”, Catton urged.  

Gauri Saxena contributed to this story

Image Credits: Public Services International/Madelline Romero, State of the World's Nursing Report 2020 Executive Summary.

Maps show (top) county level 17-year long-term average of PM2.5 concentrations (2000-2016) in the US in ug/m3 and (bottom) county level number of COVID-19 deaths per one million population in the US up to and including April 4, 2020.

People with COVID-19 are dying at significantly higher rates in communities in the United States with higher air pollution levels, according to a new Harvard University study  – the first such study to systematically examine links between air pollution and higher COVID-19 mortality. 

For every 1 microgram/ cubic meter (µg/m3) increase in average annual levels of fine PM2.5 particle pollution, COVID-19 death rates as of 4 April, 2020 were 15% higher, according to the pre-print study of death rates across some 3,080 counties of the United States, where 98% of the US population resides, by a group of researchers from the Harvard Chan School of Public Health, published Tuesday.

The strong association between higher average levels of air pollution over the past 20 years, and higher mortality rates in the ongoing COVID-19 emergency was observed even at comparatively low average annual air pollution exposure levels, of just 2-12 µg/m3 of PM 2.5.

In comparison, WHO guideline limits for PM2.5 concentrations are 10 µg/m3 annual average, although the Agency has long observed that health effects from air pollution are also observed at much lower levels.  PM 2.5 levels in some major European cities often exceed the WHO guidelines by as much as 5-10  µg/m3 or more, while air pollution levels in many low and middle-income cities may be 5-10 times above the WHO guideline levels.

The association between slighty higher levels of air pollution and much higher rates of COVID-19 mortality held firm, even after data was adjusted for a range of other variables that can also influence COVID-19 mortality such as population age and poverty rates; smoking and obesity prevalence; as well as health services availability and rates of COVID-19 testing.

“A small increase in long-term exposure to PM2.5 leads to a large increase in COVID-19 death rate, with the magnitude of increase 20 times that observed for PM2.5 and all cause mortality. The study results underscore the importance of continuing to enforce existing air pollution regulations to protect human health both during and after the COVID-19 crisis,” said the researchers, members of the Department of Biostatistics

Moreover, the association seemed to be cumulative – at least at the comparatively lower levels of air pollution common in the United States. So while higher average annual PM2.5 concentrations of 1 µg/m3 was associated with a 15% greater mortality rate, PM2.5 levels just 2 µg/m3 higher, would be associated with a 30% higher rate of COVID-19 mortality, and so on.

“We hypothesize that because long-term exposure to PM2.5 adversely affects the respiratory and cardiovascular system, it can also exacerbate the severity of the COVID-19 infection symptoms and may increase the risk of death in COVID-19 patients,” the authors concluded. “The association between PM2.5 and health including pregnancy outcomes, respiratory diseases, cardiovascular diseases, neurocognitive disease in the United States and worldwide is well established.”

Some 248 Lives Could Have Been Saved In Manhattan Alone

At the New York City epicenter of the pandemic, the researchers found that some 248 lives could have potentially been saved, so far,in the borough of Manhattan, alone, if average air pollution levels over the past 20 years had been just 1 µg/m3 lower.

Similar associations have been found for death rates in Italy, according to a another new review published by European researchers in the Environmental Pollution journal.  The study by researchers from the University of Siena and Aarhus University noted that COVID-19 mortality rates were highest in Italy’s most polluted regions, Lombardy and Emilia Romagna, at 12% compared to 4.5% in the rest of the country. However that review did not examine death rates as systematically as the Harvard study, or did it analyse against other confounders, including age, other health risk factors, and access to health services. 

Other studies of “before” and “after” pandemic satellite images have also noted that one big bonus of the COVID-19 crisis has been the cleaner skies observed over many parts of the world, from highly polluted parts of northern Italy to India and China. However, environmental health experts worry that those gains will be only temporary unless policy makers recognize more widely the huge health penalty imposed by chronic air pollution exposures -which WHO estimates kill some 7 million people every year.

On March 30, the European Public Health Association (EPHA) warned that years of exposure to air pollution may have left patients with pre-existing heart or lung conditions, rendering them more vulnerable to COVID-19. 

The statement was accompanied by satellite images showing nitrogen dioxide (NO2) air pollution levels over the Americas, Europe and Asia in March 2020 as compared to March 2019, to illustrate the blue skies impacts of COVID-19.  But the The damage is already done. Years of breathing in dirty air from traffic fumes and other sources will have weakened the health of all those who are now embroiled in a life or death fight against COVID-19,” warned Sascha Marschang, acting secretary general of the EPHA in a statement

Images combine NO2 emission readings from 5-25 March in 2019 versus the same period in 2020, based on ESA Sentinel-5 satellite data, following recommended image processing guidelines. Image credits: ESA / EPHA / James Poetzscher

Air pollution exposures lead to  chronic inflammation of the lungs, even in young and healthy subjects, and exposures over time increase the risk of acute respiratory distress syndrome – a severe manifestation of COVID-19 that leads to death, according to the authors of the European paper. Air pollution is also a factor in cardiovascular disease and stroke, as fine particles enter the blood stream as well, causing inflammation, hypertension, and increasing risks of blood clots. 

The link between COVID-19 mortality and the range of air-pollution related chronic diseases has already been well-established. Significantly higher proportions of people with acute and chronic respiratory disease, lung cancer, heart disease, and stroke, are hospitalized and eventually die from COVID-19.   But the Harvard study establishes an even more direct link.  

“The results of [our] study underscore the importance of continuing to enforce existing air pollution regulations during the COVID-19 crisis,” Harvard researchers Xiao Wu, Rachel Nethery, Benjamin Sabath, Danielle Braun, and Francesca Dominici wrote. “We anticipate a failure to do so can potentially increase the COVID-19 death toll and hospitalizations.” 

The Harvard paper was published just days after the US Administration of Donald Trump relaxed emissions requirements on new vehicles for the coming years, and just ten days after the US Environmental Protection Agency (EPA) relaxed reporting requirements for not only for air pollution emissions from factories and power plants, but also for emissions of effluents and hazardous waste materials, citing the COVID-19 emergency. The new policy sparked fears that polluters were now given a “free for all” to increase emissions, although the US EPA has since pushed back on that claim.

In one bright spot, the lower levels of nitrogen dioxide (NO2) and particulate matter (PM) from road traffic may bring “some relief” to patients currently stricken with coronavirus, according to the EPHA.

Iran & Other Countries Consider Gradual Relaxation of Lockdown 

In other developments, Iran, which has been the Eastern Mediterranean Region’s COVID-19 epicentre, may relax its nationwide business shutdown by Saturday, allowing for the resumption of  “low-risk” activities, said President Hassan Rouhani in a televised meeting. The country has been reporting about 100 fewer new cases per day over the past week. Still, 2100 new cases were reported today, and Iran remains the hardest hit country in the region, with a cumulative total of 62,589 total cases and 3,872 total deaths as of Tuesday night.

Iranian health worker disinfects bus.

In Europe, The Czech Republic announced that it would also relax lockdown measures from next Tuesday, reopening some shops and industries, and allowing limited travel abroad. The country of 10.65 million people currently has recorded 4944 cases and 87 deaths, less than a fifth of Switzerland, which has only 8.5 million people. 

Wuhan city in Hubei, China, the original epicentre of the COVID-19 pandemic, also announced that it would finally lift lockdown measures on Wednesday after more than two months in whch residents have been besieged by the virus, according to a notice posted by provincial authorities. Economic recovery is the next challenge, said Hu Chaowen, director of Hubei Province’s Poverty Alleviation Office at a press conference. He calling 2020 “the year of a decisive battle against poverty,” alluding to the economic hardships experienced by poor and day wage laborers.

In other pandemic hotspots, however,  lockdown measures were still being tightened as cases continued increasing. 

Authorities in Switzerland called on the public to maintain social distancing, saying it is too early to tell if the slowdown in new infections meant that the apex had been reach. Total COVID-19 deaths rose from 590 to 641 over the past 24 hours in a country that has 22 242 confirmed cases, for one of the the highest incidence rates of COVID-19 in Europe (259 cases/100 000 people). 

Despite initial signs that new case counts in key countries such as the United Kingdom, Italy, France and Spain, were stabilizing, others were still seeing sharp daily increases. Turkey reported some 3,148 new cases on Tuesday, for a total of 30,217. And The Republic of Belarus, which until now had very few cases at all, reported 794 total cases on Tuesday, as compared to 562 the day before.  

In an urgent attempt to stave off a wider outbreak in Belarus, a special WHO Delegation will arrive today by invitation from the President of Belarus Aleksandr Lukashenko. The Delegation will “assess the real situation, adequacy and efficiency of measures taken to prevent the spread of coronavirus the country, as well as to analyze clinical protocols and approaches to medical care”, says the National State TV and Radio Company of the Republic of Belarus. 

In the US, New York State doubled the maximum fine for violations of the state’s social distancing protocol and extended the closure of nonessential businesses and schools until the end of the month, according to a Tuesday press release from the Governor’s office. Some 1000 beds aboard the US Navy’s hospital ship the Comfort were made available to treat COVID-19 patients, following requests from New York officials to expand the ship’s mission. 

New York City experienced the “largest single day increase” in death toll of 731 deaths, said Governor Andrew Cuomo in a press briefing Tuesday. On a more positive note, however, the Governor added that the three-day average of daily hospitalization rate is reducing, and that the number of daily intensive care admissions is also “way down.

Total cases of COVID-19 as of 6:04 PM CET, with active case distribution globally. Numbers change rapidly.
WHO Maintains Position that Public Mask Use Unnecessary- Despite Increasing Evidence of Airborne Virus Transmission

In updated guidance, issued Tuesday, WHO continued to maintain that evidence of virus transmission as very fine “aerosol” particles was insufficient to justify universal use of masks by the public. However, that position is being challenged by a number of leading experts who say such airborne transmission is a possibility, and that masking helps protect healthy individuals from others who may unknowingly be COVID-19 carriers. 

While WHO has contended that the virus can only be transmitted effectively by droplets released through coughing or sneezing, Tang and other experts believe that it may also be transmitted by even tinier aerosol particles, released through the simple acts of breathing or speaking.

And since many people anyway don’t know if they are infected, universal masking would ensure that infected individuals don’t transmit transmission of the virus to other, healthy people, who are in their close proximity.

“The assumption should be that airborne transmission is possible unless experimental evidence rules it out, not the other way around”, said virologist Julian Tang at the University of Leicester, writing for Nature“If everyone can mask, it is double, two-way protection,” Tang added

Improving ventilation indoors or banning indoor meetings could be other measures helpful to preventing aerosol transmission, said scientist Lidia Morawska from the Queensland University of Technology in Australia in the Nature article.

WHO has also expressed concerns that public adoption of masks would create even greater shortages of protective equipment for health care workers, who are already desperately short. However, some health authorities, including the US Centres for Disease Control and Israel’s Ministry of Health, are also recommending that people fabricate their own cloth masks, which can be washed and reused. 

If the most vulnerable populations are guaranteed masks, the wider public could adopt masks as well, suggests Ben Cowling, an epidemiologist at the University of Hong Kong.

WHO’s Scientific brief acknowledges that airborne transmission of the virus “may be possible,” but it is limited to certain specialized medical procedures. That position is anchored in a WHO analysis of 75,465 COVID-19 cases from China from mid-February, which found that airborne transmission was “not reported.” 

“There is currently no evidence that wearing a mask (whether medical or other types) by healthy persons in the wider community setting, including universal community masking, can prevent them from infection with respiratory viruses, including COVID-19,” the WHO guidance states.

“The wide use of masks by healthy people in the community setting is not supported by current evidence and carries uncertainties and critical risks”. Medical masks should be reserved for healthcare workers. Only persons with symptoms or health personnel working under “aerosol-generating procedures” should use a mask, advises the WHO.

Commuters wear masks to protect against transmission of COVID-19 on a train in Singapore

-Svĕt Lustig Vijay and Gauri Saxena also contributed to this story

 

Image Credits: Wu et al. "Exposure to air pollution and COVID-19 mortality in the United States," Harvard University, Mina Noei, Jade Lee .

Volunteer assembles 3D- printed face shields in NYC. The face shields are donated to and sanitized before use at local hospitals facing protective equipment shortages.

WHO deferred any broad recommendation to the public on the use of face masks, even as more countries were recommending some kind of a face cover or protective mask to reduce COVID-19 transmission.

World Health Organization Director General Dr Tedros Adhanom Ghebreyesus stressed that health workers need to remain the key priority for the use of medical masks.

Dr Tedros spoke at a press briefing on Monday, where Lady Gaga also made a special appearance to announce plans for a mass virtual concert, “One World – Together At Home” on Saturday April 18th, involving dozens of celebrity stars such as Sir Elton John and Paul McCartney.

The event, in collaboration with Hugh Evans of Global Citizen,  aims to raise money for the WHO’s COVID-19 Solidarity Response Fund, particularly for test kits and protective gear to shield health workers in low- and middle-income countries from infection.

In other key comments, WHO’s head of Emergencies Mike Ryan said there is growing evidence of a strong correlation between the “dose” of viral infection to which an individual is exposed and the severity of disease that they develop, but those questions need to be explored further by researchers.

“We need to look at who is getting sick and is the type of exposure they are getting different?” said Ryan at the press briefing. “It’s not just looking at who is infected, but whether there are specific exposures that cause more severe infection. We need to have the serological-epidemiological studies to find out what the infectious dose is, and the dose of exposure, and severity of infection.

If someone is exposed to a high dose from another individual directly, or a surface that’s heavily contaminated, is that significant in terms of driving infection? We have seen that in many many other diseases in the past including cholera, Ebola and others.”

Cloth Masks & Face Covers ? WHO Refrains From Comment 

Dr Tedros said that WHO would be issuing updated guidance on masks, which so far only recommends them for health workers; people who know they are sick; or people caring for the sick.

“Use of general masks in the general population could exacerbate the supply for those who need it most. These shortages are putting health workers in real danger in some countries”, he said.

However, he noted that in some crowded, low-income settings, where other social distancing and sanitation measures are difficult to maintain, then public mask use might be more justified, adding, “What is clear is that there is limited research in this area. We encourage countries that are considering the use of masks for the general population to study their effectiveness so we can all learn. Most importantly, masks should only ever be used as part of a comprehensive package of interventions.”

The WHO Director-General offered no direct comment on the recommendations issued last week by the US Centres for Disease Control calling on the general public to wear cloth masks or other non-medical face covers. Israel also has called on the public to wear simple surgical masks, cloth masks, or cloth face covers when outside of the home, while Hungary and  Austria made wearing of masks mandatory in supermarkets.  

Public health authorities in those countries say the universal wearing of masks seems to have been a factor that helped reduce high rates of disease transmission in countries like China, the Republic of Korea, and Singapore. 

As growing evidence seems to support the fact that people who are either pre-symptomatic or asymptomatic may be unknowingly transmitting the virus, the Center for Disease Control (CDC) last week recommended wearing cloth face coverings in public settings, especially in places where adhering to social distancing guidelines are challenging, such as grocery stores and pharmacies. 

As part of the new CDC move, the US Surgeon General issued guidance on You Tube, explaining to the public how to make their own protective masks.

https://www.youtube.com/watch?time_continue=1&v=tPx1yqvJgf4&feature=emb_title

The CDC recommendation exempts young children under age of 2, people with trouble breathing, or people who are unconscious, incapacitated or otherwise unable to remove a face covering without assistance. And while it is hoped that the pervasive use of face coverings would slow the spread of the virus by carriers who are unaware that they are infected, masks will only be effective when supplemented by frequent hand cleaning with alcohol-based hand sanitizer or soap and water, CDC stressed. 

As shortages in medical supplies continue, experts stressed that medical masks, particularly high-performance N-95 masks should be mainly reserved for the healthcare workers who are on the frontlines of the pandemic.

In that vein, New York City authorities have been sending SMS messages to city residents that read: “New Yorkers: Wear a face mask when you go outside and near others. It can be a scarf, a bandana or one you make at home” However, the messages added the caveat: “The city urges you to save medical masks for our healthcare workers and first responders who truly need them.” 

Yet the new US recommendations were not without dissonance, reflecting the hesitations that some members of the public also might have over mask use, beginning with the President himself. “With the masks, it is going to be a voluntary thing. I am choosing not to do it,.” Donald Trump remarked in a press briefing after the White House issued its own recommendation echoing that of the CDC. 

Lockdowns Proving Effective for COVID-19 Control- But Exit Strategies Key to Economies

As regards lockdowns, the main disease control tool being used, Ryan said “lockdowns in many situations are proving effective in dampening outbreak, but those lockdowns are causing economic hardships. [We need ] a more sustainable way.”

He stressed, however, that any effort to lift lockdowns will require a “stepwise approach” by governments, with careful consideration of those restrictions that can safely be lifted without recharging the infection cycle. 

Among the parameters that are important to consider are hospital capacity;  the “doubling rate” – that is the number of days over which the cumulative number of COVID-19 cases are doubling; as well as the proportion of COVID-19 test sample that are testing positive.

“You need to look at doubling rate and positivity rate,” said Ryan, citing as one example of the latter, Korea, where 2-6% of samples are testing positive and restrictions on economic activity and public movements are relatively relaxed, as compared to New York City, where 37% of testing samples are turning out to be positive. 

“A carefully calibrated stepwise approach is the safe path out of lockdown.”

And once lockdowns are lifted, other tactics will become all the more important, he stressed. Those include: “active case finding, testing, isolation of cases, quarantine and strong community education around physical distancing.” 

WHO Welcomes Costa Rica Overture on Patents Pool for COVID-19 Therapies
Carlos Alvarado Quesada, President of Costa Rica

In his remarks on Monday, Dr Tedros also said that he “supported” the proposal by the President of Costa Rica, Carlos Alvarado, to create a global pool of rights to COVID-19 therapies, and would be working to finalize its details.

The WHO Director General had responded positively to the overture last week in a Tweet, but this was the first time that he made a more formal comment on the developing initiatives around an international patent pool by Costa Rica, which was also backed last week by the UN-supported Medicines Patent Pool.

“I want to thank the Medicines Patent Pool and UNITAID for the initiative they announced last Friday to include medicines and diagnostics for COVID-19 in their licensing pool,” he said.

In a parallel move, the International Federation of Pharmaceutical Manufacturers (IFPMA) and Associations on Monday released a statement responding favorably to the Medicines Patent Pool’s move.

“While we are not aware of any instance to date where intellectual property management has been an impediment in the global response to this pandemic, proposals for voluntary pooling of intellectual property assets, including the decision of the Medicines Patent Pool (MPP) to temporarily expand its mandate to include health technologies related to COVID-19, adds to the arsenal of options available to companies when establishing access to any potential COVID-19 product,” said Thomas Cueni, director-general of IFPMA.

Cueni added that the biopharma industry “recognized there was no ‘one-size fits all’ approach” to supporting research and development, and access efforts. Thus, the industry was “open to explore innovative approaches and partnerships to facilitate further R&D to develop new medicines and vaccines for patients suffering from COVID-19 and to expand access.”

Dr Tedros also thanked the President of Costa Rica, Carlos Alvarado, and Health Minister Daniel Salas for submitting the proposal to create a pool of rights to diagnostics, treatments and vaccines, with free access or licensing on “reasonable and affordable terms.”

“Muchas gracias, Mr President. I support this proposal, and we are working with Costa Rica to finalize the details,” added the WHO Director-General.

“More than 70 countries have joined WHO’s Solidarity Trial to accelerate the search for an effective treatment. And about 20 institutions and companies are racing to develop a vaccine. WHO is committed to ensuring that as medicines and vaccines are developed, they are shared equitably with all countries and people,” he added.

India bans Hydroxychloroquine Exports – Following Despite US Efforts to Access Supplies  

Despite the calls for global solidarity, individual countries continued moves to restrict exports of certain supplies and medicines viewed as potentially critical. Over the weekend, India banned all export of the drug hydroxychloroquine, a drug currently approved for the treatment of immune disorders such as lupus, but also viewed as a potential remedy for COVID-19.

The Indian limitation on exports followed a new, and unprecedented recommendation by a National Task Force for COVID-19, led by the Indian Medical Research Council, on the use of hydroxychloroquine as a prophylactic for asymptomatic healthcare workers involved in the care of suspected or confirmed cases of COVID-19, as well as for asymptomatic houseold contacts of laboratory confirmed COVID-19 cases. 

Over the weekend, the Indian Ministry of Health and Family Welfare issued a more formal guidance permitting the off-label use of hydroxychloroquine with the antibiotic azithromycin in COVID-19 for patients in intensive care or with severe respiratory disease

“The export of hydroxychloroquine and formulations made from hydroxychloroquine shall remain prohibited, without any exception,” stated the order by India’s Directorate General of Foreign Trade in the wake of the national policy directives.  

The Indian export ban was imposed despite US President Trump’s call this weekend with Indian PM Narendra Modi during which Trump urged the release of “the amounts that we ordered”.

Although hydroxychloroquine’s safety and efficacy for treating COVID-19 have not been demonstrated, various countries, including India and the US, have incorporated the antimalarial drug into their national containment plans.

The pharmaceutical industry is not waiting for the final evidence either. It has already made commitments to ramp up production of the drug. Pharmaceutical giants like Novartis, Bayer, Teva and Mylan NV, amongst others, have all pledged to contribute some 220 million tablets, by mid-May, more than half of which will be donated by the Swiss-based pharma firm Novartis.

New York may be Reaching Plateau – Africa doing “Well” So Far In Response

In terms of pandemic trends worldwide, it appeared that New York may be near the apex of its infection wave, or already plateauing, New York Governor Andrew Cuomo said on  Sunday. New York City’s daily number of deaths dropped for the first time in weeks from 630 on Saturday to 594 on Sunday, and the number of new hospitalizations was halved overnight.

“The number of deaths over the past few days has been dropping for the first time. What is the significance of that? It’s too early to tell”, Cuomo said in yesterday’s speech.

“Three or four days” may be needed to see whether the death rate is actually decreasing. Some 4,150 people have died among the 122,031 confirmed cases in the USA’s epicentre, the Governor said. 

However, cases are rising fast elsewhere in the US – and President Trump is facing mounting pressure from healthcare groups to put a national shelter-in-place order. So far, stay at home orders have been up to state governors’ discretion. Yesterday, Texas officials installed COVID-19 Checkpoints at the border with Louisiana. Vehicles are screened at all roadways crossing into Texas including interstates .Commercial motor vehicle traffic will not be obstructed, says Louisiana’s State Police. Louisiana’s case count shot up, almost doubling over the past weekend.

Africa has been doing “well in the outbreak response so far,” said Mike Ryan, WHO Executive Director of the Health Emergencies Programme, at today’s press conference. Even so, the number of cases in the African region have doubled over the past last week, with a total of some 9 200 cases as of Monday. 

There were even more worrisome trends in some countries; the number of infected people in Guinea, Niger and Cameroon doubled over the past 2-3 days, a faster pace of growth than most other countries today. South Sudan also reported cases of COVID-19 for the first time, according to the latest WHO Situation Report.

Still, some African countries still only have imported cases, leaving a window to contain further disease expansion, said Maria Van Kerkhove, WHO’s Technical Lead for the COVID-19 outbreak, at Monday’s press briefing.

Responding to a journalist’s suggestion in a TV interview last week that Africa could be the ideal test ground for a possible COVID-19 vaccine, Dr Tedros said, “Africa can’t and won’t be a testing ground for any vaccine.”

He described the remarks as a “hangover from a colonial mentality.”

“It was a disgrace, appalling, to hear during the 21st Century, to hear from scientists, that kind of remark. We condemn this in the strongest terms possible, and we assure you that this will not happen,” he added.

The offensive remarks were made during a discussion on French TV channel LCI, as Camille Locht, head of research at Inserm Health Research group, talked about a possible vaccine trial in Europe and Australia.

Jean-Paul Mira, head of intensive care at Cochin hospital in Paris, then said: “If I can be provocative, shouldn’t we be doing this study in Africa, where there are no masks, no treatments, no resuscitation?

“A bit like it is done elsewhere for some studies on AIDS. In prostitutes, we try things because we know that they are highly exposed and that they do not protect themselves.”

Mr Locht nodded in agreement at this suggestion, and said: “You are right. We are in the process of thinking about a study in parallel in Africa.”

Cochin later apologized for the remark.

There is still a window of time in Africa, as some countries only have imported cases, rather than local transmission.
Spain & Italy Stabilizing – UK Public Warned to Prepare for Worst

In the United Kingdom, the public was warned to prepare for the worst as cases were still rapidly increasing, and Prime Minister Boris Johnson was moved to the intensive care unit  Monday night, following ten days of COVID-19 self-quarantine and a deterioration in his health status. Concurrently,  Queen Elizabeth II addressed the nation in a rare, and well-received speech on Sunday.

Spain’s cases and deaths continue to fall for the fourth day in a row, as the Spanish government continued to bolster its efforts on testing, including with the rollout of new rapid tests.

“Throughout the day, the first part of a million rapid tests will be received by the Autonomous Communities,” said Spanish Health Minister Salvador Illa. In an effort to counter the economic effects of the Covid-19, the Spanish government also announced plans to guarantee a universal basic income to all citizens.  

Italy’s infections rates also seemed to be finally declining, after the numbers first began to plateau over the past week. With the flattening of Italy’s curve following a month of lockdown, the Italian authorities were debating if and how to let some members of the workforce return to work, focusing first on people who could be tested and found to have antibodies against COVID-19.

Lately, Belarus has witnessed the most rapid growth of coronavirus in Europe, with cases having doubled in only three days. There is no need to stop normal daily life, said the Belarusian President Alexander Lukashenko president in an interview with The Times, who even recommended a glass of vodka for lunch to citizens. The Eastern European country has not imposed a lockdown and has not closed its borders. Belarus currently has some 560 cases.

Today, Japan announced a national state of emergency after the country experienced the  highest daily jump in cases on Sunday, with numbers soaring to 1000 cases. Many of Tokyo’s cases are untraceable, said Governor Yuriko Koike said in a livecast YouTube video on yesterday, according to a report from Reuters. 

Total cases of COVID-19 as of 6:55 PM CET, with active case distribution globally. Numbers change rapidly.

Image Credits: HP-Watch/G Ren, Africa CDC.

The European Medicines Agency on Friday issued new guidance supporting the use of Gilead Sciences’ antiviral remdesivir as a COVID-19 treatment under compassionate use programmes.

The new EMA guidelines on remdesivir recommend its compassionate use  in adult COVID-19 patients experiencing severe disease requiring invasive mechanical ventilation.

Such compassionate use programmes are set up by individual country governments to allow patients suffering from life-threatening diseases access to experimental treatments that have not yet received full marketing approval. However, the EMA  issued specific guidance for remdesivir after Estonia, Greece, the Netherlands, and Romania requested an opinion from the agency’s Committee for Medicinal Products for Human Use (CHMP) on compassionate use protocols.

While large, randomized clinical trials remain the “gold standard” for assessing the safety and efficacy of investigational treatments, the EMA acknowledged the need for a ” harmonised approach to compassionate use in the EU to allow access to remdesivir for patients who are not eligible for inclusion in clinical trials,” said Harald Enzmann, chair of the CHMP in a press release.

The CHMP further encouraged Gilead to make remdesivir available in a “fair and transparent” way to all EMA Member States that wished to take part in clinical trials or use the drug under compassionate use.

The EMA move came as controversy continued to swirl around Gilead’s rights to remdesivir in light of growing demand for the investigational treatment. Medicines access advocates have argued that exclusive patent rights on COVID-19 technologies could result in shortages of essential new treatments or vaccines in an accelerating global crisis.

The company just opened an “expanded access” program after temporarily suspending its own “compassionate use” program due to an overwhelming flood of requests from COVID-19 patients unable to enroll in clinical trials.

Under the expanded access program, hospitals and physicians can apply for emergency use of remdesivir for multiple severely ill patients at the same time. Gilead’s own “compassionate use” program will continue, but enroll only pregnant women and children, Gilead CEO Daniel O’Day wrote in a statement.

Medicines Patent Pool Expands Mandate to Support Establishment Of IP “Pool” for COVID-19 Technologies

Meanwhile, the respected Medicines Patent Pool (MPP) threw its support behind a global initiative to create a World Health Organization-led “pool” of intellectual property rights for COVID-19 technologies, saying that it could help facilitate efforts to make key COVID-19 technologies more widely available to countries as they come to market. 

The UN-backed Medicines Patent Pool (MPP) works as an intermediary between pharma companies and global health agencies such as WHO and UNAIDS, to increase access to treatments for HIV/AIDs, hepatitis C, and tuberculosis. MPP negotiates with patent holders for voluntarily licenses of their products to MPP, which then “pools” the intellectual property rights so that generic manufacturers can enter the market. 

While primarily focused on medicines access, the MPP Governance Board temporarily expanded its mandate on Friday to include all potential COVID-19 health technologies, which could potentially include diagnostics and vaccines. With support from Unitaid, MPP’s founding organization, this allows the organisation to contribute IP and licensing expertise on any relevant COVID-19 products to the World Health Organization.

Unitaid’s Board issued an open letter last week supporting Costa’s Rica’s call for the WHO to create a pool of patents for COVID-19 related technologies.

“In these difficult times, the MPP Board recognises the important role that MPP can play to increase access to life-saving products for those who need them most. And importantly, with time of the essence, to ensure that we make use of the expertise and mechanisms that already exist,” said Marie-Paule Kieny, chair of the MPP Board, in a press release.

“The Medicines Patent Pool, set up and funded by Unitaid a decade ago, has a proven track record and is immediately available to the WHO to begin this urgent work,” said Marisol Touraine, chair of the Unitaid Executive Board, reiterating Unitaid’s support for a global “pool” of intellectual property rights.

The organisation aims to follow the lead of WHO, which is currently exploring with other stakeholders the implications of a global “pool” of intellectual property rights, a spokesperson for MPP told Health Policy Watch.

140 Organizations, Researchers, & Educators Call On WIPO To Ensure Intellectual Property Frameworks Support COVID-19 Response

In a parallel move, some 140 organizations, researchers, educators, and students called on the World Intellectual Property Organization to provide clear guidance to governments on using intellectual property laws to support the COVID-19 response.

The COVID-19 pandemic has shone a bright light on how important intellectual property limitations and exceptions can be to development and human flourishing,” the organizations stated in an open letter to WIPO Director General Francis Gurry. For example, data sharing has facilitated cross-border collaboration on COVID-19 research. Schools, universities, libraries, museums, and other research institutions are transferring materials online in the wake of widespread closures. However, remote access to such materials is only available where copyright laws permit. 

WIPO, as the leading agency on global intellectual property, should step in and issue guidance to governments in response to any thorny “intellectual property issues that the coronavirus is raising,” the organizations say.  

The letter suggests WHO take four steps:

  1. Encourage WIPO member states to take advantage of intellectual property flexibilities to increase access to protected works for online learning and research;
  2. Request right holders to remove licensing restrictions that inhibit remote learning, research, and access to culture to both help address the global pandemic and minimise disruption caused by it;
  3. Support the call by Costa Rica for the World Health Organization to pool intellectual property rights for all COVID-19 related technologies and promote use of the Medicines Patent Pool;
  4. Support countries’ rights to enact and use exceptions to trade secret and IP rights to facilitate access to data and technologies needed to increase equitable access to COVID-19 technologies.

Image Credits: Medicines Patent Pool.